SCHEMBL5651200

SCHEMBL5651200

N#Cc1ccc2c(c1)C[C@H](NS(=O)(=O)c1ccccc1)C(=O)N2Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FNTA P49354 8/20 0.49
FNTB P49356 8/20 0.49
THRB P10828 1/20 0.48
NPY1R P25929 1/20 0.46
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
ALOX12 P18054 1/20 0.41
F10 P00742 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
XIAP P98170 1/20 0.37
NR1H2 P55055 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651206 1.00 FNTA (0.49) FNTAFNTBTHRBNPY1RKDM4E
SCHEMBL5653807 0.92 THRB (0.43) FNTAFNTBTHRBNPY1RKDM4E
SCHEMBL10183595 0.85 NPY1R (0.47) NPY1RALDH1A1F10SMN1; SMN2MEN1
SCHEMBL5132775 0.85 ALDH1A1 (0.48) NPY1RALDH1A1F10SMN1; SMN2MEN1
SCHEMBL649728 0.85 ALDH1A1 (0.48) NPY1RALDH1A1F10SMN1; SMN2MEN1
SCHEMBL649727 0.85 ALDH1A1 (0.48) NPY1RALDH1A1F10SMN1; SMN2MEN1
SCHEMBL5655084 0.85 NPY1R (0.47) NPY1RALDH1A1F10SMN1; SMN2MEN1
SCHEMBL5133148 0.85 NPY1R (0.47) NPY1RALDH1A1F10SMN1; SMN2MEN1
SCHEMBL5134064 0.84 NPY1R (0.54) NPY1RALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL5133139 0.79 NPY1R (0.43) NPY1RALDH1A1F10SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7276608-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2007-10-02 US disclosed
US-7276608-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2007-10-02 US disclosed
US-20050009870-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009870-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators CNR2, CNR1, OPRL1 FNTA 1368/4885FNTB 2071/4885THRB 809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.